Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06900595)

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer: a one-minute explainerNCT069005951 min

Biospecimen Collection trial for Locally Advanced Adrenal Cortical Carcinoma (NCT06900595). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 12 or older with unresectable locally advanced, recurrent or metastatic adrenocortical cancer. Up to three prior treatment lines are allowed, but prior CTLA-4/PD-1/PD-L1 immunotherapy or MET inhibitors exclude participation.

The idea: randomly compare daily oral cabozantinib with or without intravenous cemiplimab every three weeks. Cabozantinib blocks growth signals; cemiplimab supports an immune attack. Researchers measure time before cancer progression or death.

This phase 2 study plans 48 patients. NCI sponsors it; 81 US sites are recruiting, including Phoenix.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.